Immusoft
Business Services · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
454 N 34th St, Seattle, Washington, 9810...Phone Number
(206) 931-0262Website
www.immusoft.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Immusoft
Immusoft Corporation's mission is to treat diseases using its technology platform called Immune System Programming. The technology modifies a patient's B cells and instructs the cells to produce gene-encoded medicines. Immusoft Corporation is based in Seattle, Washington.Explore more
Immusoft Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immusoft your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Immusoft
Immusoft, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Immusoft is spiking on competitors!
Funding: Get notified immidiatlly once Immusoft has new funding data
Earning: See what the market has to say on Immusoft recently announced quarterly report
Check if Immusoft has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Immusoft had a recent Job posting/layoffs
Product Launch: Get notified when Immusoft launches new products
Recommended Actions
Find VP level buyers at Immusoft
Find 3 more new buyers
Compare Similar Companies to Immusoft
Compare insights from companies similar to Immusoft, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immusoft is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immusoft is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immusoft.
Immusoft financials insights
Gather financial insights about Immusoft, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$2.4M
2016
Series A
$2.7M
2019
Series B
$20M
2020
Debt
$150K
2023
Other Financing Round
$8M
Immusoft Tech Stack
A closer look at the technologies used by Immusoft
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Person-Based
Sean Ainsworth, Chief Executive Officer & Chairman, appeared on a podcast called "Business Of Biotech" on 12/08/2025. Topics discussed include B cell engineering, biotech entrepreneurship, FDA therapies.
Events, Podcast
Event
Events
Funding
Funding
Immusoft News & Media
Immusoft Announces Presentation of World's First Patient Treated with an Engineered B Cell Therapy at Workshop Co-Hosted by FDA and ARM
Prospectively designed for scalability and re-dosability, Immusoft’s engineered B cells represent the next generation of advanced therapeutics Prospectively designed for scalability and re-dosability, Immusoft’s engineered B cells represent the next generation of advanced therapeuticsImmusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine
Funding will enable the Company to support expanded development of its lead asset, ISP-001, for the treatment of mucopolysaccharidosis type 1 Funding will enable the Company to support expanded development of its lead asset, ISP-001, for the treatment of mucopolysaccharidosis type 1Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II
Designation recognizes ISP-002, an engineered B cell therapy designed for sustained enzyme delivery SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug...Immusoft Secures FDA Orphan Drug Designation for ISP-002 in MPS II, a Progressive Lysosomal Storage Disease
Orphan Drug Designation for MPS II builds on Immusoft's clinical progress in MPS I and supports expansion of its engineered B cell platform across multiple indications SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immusoft
Sign Up For FreeTo access detailed company insights
Immusoft Corporation's mission is to treat diseases using its technology platform called Immune System Programming. The technology modifies a patient's B cells and instructs the cells to produce gene-encoded medicines. Immusoft Corporation is based in Seattle, Washington.... Read More
